Dermal Wound - Healing Genes

Dermal Wound

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

RES Prepared With RECELL® Compared to Conventional Care for Healing of Donor Sites in Ages 1-16 Years

A Prospective Multicenter Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of RES (Regenerative Epidermal Suspension) Prepared With the RECELL® Device Compared to Conventional Care for Healing of Donor Sites in Infants, Children and Adolescents (Aged 1-16 Years)

Phase Not Applicable


Doctors at the Arizona Burn Center are investigating the comparative healing time at skin donation sites (for burn patients) when standard dressings are used versus the RECELL® System regenerative epidermal suspension spray. RECELL isolates skin cells from a small skin sample and immerses it in an enzyme solution to produce Spray-On Skin™ Cells. The regenerative epidermal suspension includes the key skin cells which play a critical role in healing.

Participants will be assigned to either receive the experimental treatment or standard wound dressings, and donor site wound closure will be followed for up to 52 weeks.


  • Be 1 to 16 years of age
  • The area of total injury or planned defect (excluding donor sites) is 5% to 25% Total Body Surface Area (TBSA), inclusive
  • Two discrete donor sites of similar size (± 25%) can be created in a similar non-articulating location (excluding the scalp) with each donor site representing a minimum of 1% TBSA


  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings (or only the same dressings, if assigned that treatment).
  3. Donor site wound closure will be followed for up to 52 weeks.


Trials will take place at the Arizona Burn Center at Maricopa Integrated Health Systems in Phoenix, AZ. Map.


Contact: Elizabeth Kirshner  |  661-877-6869  |  [email protected]

Contact: Lisa Carothers  |  661-568-1311  |  [email protected]



Avita Medical

Biomedical Advanced Research and Development Authority


Or go online:



Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader